Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA (2016 - 2021)

Historic EBITDA for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $22.2 million.

  • Neurocrine Biosciences' EBITDA rose 13762.71% to $22.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $36.5 million, marking a year-over-year decrease of 6156.15%. This contributed to the annual value of $40.4 million for FY2019, which is 9191.12% up from last year.
  • As of Q3 2021, Neurocrine Biosciences' EBITDA stood at $22.2 million, which was up 13762.71% from $42.0 million recorded in Q2 2021.
  • Neurocrine Biosciences' EBITDA's 5-year high stood at $85.6 million during Q2 2020, with a 5-year trough of -$100.4 million in Q1 2019.
  • Over the past 5 years, Neurocrine Biosciences' median EBITDA value was $20.2 million (recorded in 2018), while the average stood at $4.1 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' EBITDA plummeted by 32350.74% in 2017, and later surged by 113880.6% in 2019.
  • Neurocrine Biosciences' EBITDA (Quarter) stood at $5.6 million in 2017, then surged by 226.32% to $18.2 million in 2018, then soared by 85.46% to $33.8 million in 2019, then plummeted by 274.78% to -$59.0 million in 2020, then skyrocketed by 137.63% to $22.2 million in 2021.
  • Its last three reported values are $22.2 million in Q3 2021, $42.0 million for Q2 2021, and $31.3 million during Q1 2021.